Skip to content

You can have confidence in your biosimilar medicines

Learn more
Switching to biosimilars is safe and effective for patients
Learn more
Previous
Next

Who we are

Biosimilars Canada is a national association representing the biosimilar medicines industry in Canada. We provide leadership in educating Canadian stakeholders about the safety and efficacy of biosimilar medicines, and advocate for policies that support their timely approval, reimbursement, market acceptance and expanded use.

About Biosimilars

As patents for original brand biologic medicines expire other manufacturers can produce new versions called biosimilars. Health Canada authorizes biosimilars for sale using the same rigorous regulatory standards as for all other biologic drugs, and there are no clinically meaningful differences in efficacy and safety between a biosimilar and the original brand biologic medicine.

Resources

Learn more about biosimilars and their benefits for patients and healthcare systems.

Latest news

IGBA Launches First Global Biosimilars Week

Biosimilars Canada is participating in this globally aligned educational initiative to raise awareness of biosimilar medicines from November 16 to 20.

Read more

New study by the Ontario Drug Policy Research Network

A new study by the Ontario Drug Policy Research Network found that provinces could save up to $426 million by implementing biosimilar switching policies.

Read more

Favouring generics and biosimilars to reduce the bill for group benefit plans

Op-ed in Advantages magazine by Jim Keon, President of the Canadian Generic Pharmaceutical Association and its Biosimilars Canada division, which highlights the benefits of expanding the use of generic and biosimilar medicines for group drug benefit plans. Available in French only.

Read more